Center-Authored Papers

Filters: Author is Appelbaum, Fredrick R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Yttrium Radioisotopes
Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC.  2005.  Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.. Clinical cancer research : an official journal of the American Association for Cancer Research. 11(2 Pt 1):787-94. Abstract
Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, King DJ, Haines AM, Hamann P, Hinman L et al..  1996.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.. Cancer research. 56(9):2123-9. Abstract
Pagel JM, Matthews DC, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Gopal AK, Lin Y, Saganic L, Appelbaum FR et al..  2009.  Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.. Cancer research. 69(1):185-92. Abstract
Young Adult
Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, Hansen JA, Salter AI, Lansverk E, Stewart FM et al..  2010.  Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(7):1276-82. Abstract
Furlong T, Martin PJ, Flowers MED, Carnevale-Schianca F, Yatscoff R, Chauncey TR, Appelbaum FR, Deeg HJ, Doney K, Witherspoon RP et al..  2009.  Therapy with mycophenolate mofetil for refractory acute and chronic GVHD.. Bone marrow transplantation. 44(11):739-48. Abstract
Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW et al..  2011.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7. Abstract
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract
Gooley TA, Chien JW, Pergam SA, Hingorani SR, Sorror ML, Boeckh MJ, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR et al..  2010.  Reduced mortality after allogeneic hematopoietic-cell transplantation.. The New England journal of medicine. 363(22):2091-101. Abstract
McCune JS, Batchelder A, Guthrie KA, Witherspoon RP, Appelbaum FR, Phillips B, Vicini P, Salinger DH, McDonald GB.  2009.  Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.. Clinical pharmacology and therapeutics. 85(6):615-22. Abstract
Inamoto Y, Flowers MED, Lee SJ, Carpenter PA, Warren EH, Deeg HJ, Storb R, Appelbaum FR, Storer BE, Martin PJ.  2011.  Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.. Blood. 118(2):456-63. Abstract
Sanders JE, Hoffmeister PA, Storer BE, Appelbaum FR, Storb R, Syrjala KL.  2010.  The quality of life of adult survivors of childhood hematopoietic cell transplant.. Bone marrow transplantation. 45(4):746-54. Abstract
Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA et al..  2011.  Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.. Blood. 118(17):4561-6. Abstract
Loggers ET, Starks H, Shannon-Dudley M, Back AL, Appelbaum FR, Stewart FM.  2013.  Implementing a Death with Dignity program at a comprehensive cancer center.. The New England journal of medicine. 368(15):1417-24. Abstract
Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, Gooley TA, Brown ML, Koo KKW, Rosinski KV et al..  2010.  Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.. Blood. 115(19):3869-78. Abstract
Gutman JA, Leisenring WM, Appelbaum FR, Woolfrey AE, Delaney C.  2009.  Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(9):1122-9. Abstract
Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem H-P, Petersdorf EW, Pereira S, Nash RA, Mielcarek M, Fero ML et al..  2011.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.. Blood. 117(11):3214-9. Abstract
Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, Flowers MED, Syrjala KL, Hansen JA, Storb R et al..  2010.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(6):1011-6. Abstract
Deeg HJ, Appelbaum FR.  2011.  Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis.. Blood. 117(26):7185.
Mielcarek M, Storer BE, Boeckh MJ, Carpenter PA, McDonald GB, Deeg HJ, Nash RA, Flowers MED, Doney K, Lee SJ et al..  2009.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.. Blood. 113(13):2888-94. Abstract
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA et al..  2010.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.. Blood. 115(3):453-74. Abstract
Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler VG et al..  2010.  Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(5):909-13. Abstract
Doney K, Gooley TA, Deeg HJ, Flowers MED, Storb R, Appelbaum FR.  2011.  Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(8):1187-95. Abstract
Rotta M, Storer BE, Storb R, Martin PJ, Flowers MED, Vernon MS, Peffer A, Maloney DG, Deeg HJ, Sandmaier BM et al..  2010.  Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10):1463-6. Abstract
Rotta M, Storer BE, Storb R, Martin PJ, Heimfeld S, Peffer A, Maloney DG, Deeg HJ, Sandmaier BM, Appelbaum FR et al..  2010.  Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.. Blood. 115(6):1288-95. Abstract
Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract